Market Overview

UPDATE: Stifel Nicolaus Initiates Zimmer Holdings at Hold; More Diversification Needed

Related ZMH
Zimmer Provides Update On The European Commission Review Process Relating To The Pending Merger With Biomet, Inc.
Zimmer Announces FDA Clearance Of The Stand-alone Optio-C Anterior Cervical System For Use With Structural Allograft/Autograft

Stifel Nicolaus initiated coverage on Zimmer Holdings (NYSE: ZMH) with a Hold rating.

Stifel Nicolaus commented, "In our view, ZMH has lagged its competition in diversifying its business model, especially in expanding its emerging market exposure. At ZMH's current share price/valuation, these concerns surrounding strategic issues and possible competitive ‘headwinds” (Johnson & Johnson's, JNJ, $69.19, Hold, hips rebounding post-ASR XL Aectabular System controversies) offset potential economically-driven knee franchise re-acceleration from the full 2013 Persona knee launch. These concerns make us inclined to wait for a more compelling price entry point before turning more positive on the stock."

Zimmer Holdings closed at $64.44 on Monday.

Latest Ratings for ZMH

DateFirmActionFromTo
Dec 2014Leerink SwannMaintainsOutperform
Dec 2014BarclaysMaintainsOverweight
Oct 2014JP MorganMaintainsNeutral

View More Analyst Ratings for ZMH
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (ZMH)

Around the Web, We're Loving...

Get Benzinga's Newsletters